Exclusive Summary

• - Off-patent in most markets with first generics since ~2016; 500 mg lyophilized vial faces no patent barriers for rapid distribution entry.
• - Targets hard-need inpatients with MRSA bacteremia/right-sided endocarditis and severe cSSTI, addressing ~0.1–0.6 million MRSA bacteremia cases annually worldwide.
• - Listed on the WHO Essential Medicines (AWaRe Reserve) and recommended by IDSA/other guidelines; once-daily dosing with bactericidal Gram-positive activity.
• - US FDA-GMP and US registration provide strong compliance credibility, enabling reliance pathways and smoother tender access.
• - Typical 60–90% discount vs originator, delivering compelling cost-effectiveness across both developed and emerging markets.